Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. lactis (BB-12 / HN019) vs Semaglutide: B. lactis (BB-12 / HN019) has the stronger overall evidence (6 vs 8.5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
B. lactis (BB-12 / HN019) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
1-10 billion CFU daily for BB-12 (1 billion is enough); 10-20 billion CFU daily for HN019 if transit is the goal
any
Capsule or sachet standardized to a named strain (BB-12 or HN019)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
2 weeks
4 weeks
n/a
n/a
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.
Scand J Gastroenterol (2011) · Rct · n=100
Whole-gut transit fell 49 to 21 hours on high dose (p<0.001) and 60 to 41 hours on low dose (p=0.01); placebo unchanged
Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.
JAMA Netw Open (2024) · Rct · n=229
Primary outcome (change in complete spontaneous bowel movements per week): +0.80 with HN019 vs +0.66 placebo — no difference
Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial.
Gut Microbes (2018) · Rct · n=228
No significant differences vs placebo in the primary outcome (colonic transit time) or any secondary outcome
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
B. lactis (BB-12 / HN019) has a higher evidence score (6/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between B. lactis (BB-12 / HN019) and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.